Physician profile
Lawrence Williams
NPI 1336140052
$11,795.75
in general payments reported to CMS, 2019-2025
55 companies · $980 in 2025
The $980 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,273 · 2020: $1,308 · 2021: $2,189 · 2022: $1,935 · 2023: $2,118 · 2024: $1,993 · 2025: $980.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,091.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,091.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,464.96 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $1,233.95 | 2019-2025 | Vraylar, Qulipta, Ubrelvy |
| Lilly USA, LLC | $1,045.23 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Astrazeneca Pharmaceuticals LP | $756.99 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Astellas Pharma US INC | $743.60 | 2019-2025 | Veozah, Myrbetriq |
| Novartis Pharmaceuticals Corporation | $571.80 | 2019-2025 | |
| Amgen INC. | $536.81 | 2019-2024 | Repatha, Otezla, Evenity |
| Bayer Healthcare Pharmaceuticals INC. | $466.91 | 2022-2025 | |
| Pfizer INC. | $410.36 | 2019-2025 | |
| Amarin Pharma, INC. | $365.73 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $358.19 | 2019-2024 | Trintellix |
| Eisai INC. | $343.76 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $291.06 | 2019-2022 | |
| Ardelyx, INC. | $260.85 | 2024-2025 | Ibsrela |
| Boehringer Ingelheim Pharmaceuticals, INC. | $258.21 | 2019-2025 | Jardiance |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.